Many cancer patients may need a sequential one-two punch of immunotherapies

(La Jolla Institute for Immunology) New research led by scientists at La Jolla Institute for Immunology (LJI) and the University of Liverpool may explain why many cancer patients do not respond to anti-PD-1 cancer immunotherapies--also called checkpoint inhibitors.The team reports that these patients may have tumors with high numbers of T follicular regulatory (Tfr) cells.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news